Vitali Pool

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. ncbi request reprint Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States
    Vitali Pool
    Vaccine Safety and Development Activity, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 110:e71. 2002
  2. ncbi request reprint Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS)
    Michelle Russell
    Immunization Safety Branch, NIP CDC, Mail Stop E61, Atlanta, GA 30333, USA
    Vaccine 23:664-7. 2004
  3. doi request reprint Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003
    Armenak Asatryan
    Science Applications International Corporation and Emory University School of Medicine, Atlanta, GA, USA
    Vaccine 26:1166-72. 2008
  4. ncbi request reprint Data mining in the US using the Vaccine Adverse Event Reporting System
    John Iskander
    Office of Immunization Safety, Office of the Chief Science Officer, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Drug Saf 29:375-84. 2006
  5. ncbi request reprint Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS)
    Lauren DiMiceli
    Immunization Safety Branch, NIP CDC, Mail Stop E61, Atlanta, GA 30333, USA
    Vaccine 24:703-7. 2006
  6. ncbi request reprint A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001
    Weigong Zhou
    Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pharmacoepidemiol Drug Saf 13:505-10. 2004
  7. ncbi request reprint Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001
    Weigong Zhou
    Epidemic Intelligence Service Program, Epidemiology Program Office, CDC, USA
    MMWR Surveill Summ 52:1-24. 2003
  8. ncbi request reprint Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data
    Jens U Ruggeberg
    Pädiatrische Infektiologie, Universitätskinderklinik Düsseldorf, Germany
    Vaccine 25:5675-84. 2007
  9. ncbi request reprint Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data
    Robert P Wise
    Food and Drug Administration, Rockville, MD, USA
    Vaccine 25:5717-24. 2007
  10. ncbi request reprint Safety of influenza vaccination during pregnancy
    Vitali Pool
    Am J Obstet Gynecol 194:1200; author reply 1201. 2006

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States
    Vitali Pool
    Vaccine Safety and Development Activity, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 110:e71. 2002
    ....
  2. ncbi request reprint Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS)
    Michelle Russell
    Immunization Safety Branch, NIP CDC, Mail Stop E61, Atlanta, GA 30333, USA
    Vaccine 23:664-7. 2004
    ..Given the large number of immunizations administered every year in the US, the reported risk of allergic reactions possibly due to latex contamination of vaccines appears to be very small...
  3. doi request reprint Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003
    Armenak Asatryan
    Science Applications International Corporation and Emory University School of Medicine, Atlanta, GA, USA
    Vaccine 26:1166-72. 2008
    ..Thus, HL following MMCV has been reported in the literature and to the VAERS. Further studies are needed to better understand if there is a causal relationship between MMCV and HL...
  4. ncbi request reprint Data mining in the US using the Vaccine Adverse Event Reporting System
    John Iskander
    Office of Immunization Safety, Office of the Chief Science Officer, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Drug Saf 29:375-84. 2006
    ..Such approaches are needed as more new vaccines continue to be licensed...
  5. ncbi request reprint Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS)
    Lauren DiMiceli
    Immunization Safety Branch, NIP CDC, Mail Stop E61, Atlanta, GA 30333, USA
    Vaccine 24:703-7. 2006
    ..Nevertheless, yeast associated anaphylaxis after HBV in sensitized patients appears to be a rare event...
  6. ncbi request reprint A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001
    Weigong Zhou
    Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pharmacoepidemiol Drug Saf 13:505-10. 2004
    ..We reviewed reports in the Vaccine Adverse Event Reporting System (VAERS) to assess if parenteral inactivated influenza vaccines (influenza vaccines) may also increase the risk for Bell's palsy...
  7. ncbi request reprint Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001
    Weigong Zhou
    Epidemic Intelligence Service Program, Epidemiology Program Office, CDC, USA
    MMWR Surveill Summ 52:1-24. 2003
    ..Therefore, postmarketing monitoring of adverse events after vaccinations is essential. The cornerstone of monitoring safety is review and analysis of spontaneously reported adverse events...
  8. ncbi request reprint Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data
    Jens U Ruggeberg
    Pädiatrische Infektiologie, Universitätskinderklinik Düsseldorf, Germany
    Vaccine 25:5675-84. 2007
  9. ncbi request reprint Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data
    Robert P Wise
    Food and Drug Administration, Rockville, MD, USA
    Vaccine 25:5717-24. 2007
  10. ncbi request reprint Safety of influenza vaccination during pregnancy
    Vitali Pool
    Am J Obstet Gynecol 194:1200; author reply 1201. 2006